VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the publication of a peer-reviewed paper in Critical Care Medicine reporting that its Nu.Q NETs H3.1 biomarker serves as an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. This finding underscores the biomarker's potential for risk stratification and early intervention, which could significantly impact patient outcomes.
The study, which analyzed patient samples, found significantly higher Nu.Q NETs H3.1 levels in septic shock patients compared to those with sepsis alone. Additionally, the research revealed a dose-response relationship between the biomarker and acute kidney injury severity, suggesting that higher levels correlate with more severe organ dysfunction. The journal also published an independent editorial that examined H3.1 nucleosomes as a potential marker of NET-mediated organ injury, further validating the scientific relevance of the findings.
Sepsis is a life-threatening condition that arises when the body's response to infection causes widespread inflammation, leading to organ failure. Early identification of high-risk patients is crucial for timely and effective treatment. The Nu.Q NETs test, which quantifies nucleosomes released during NETosis—a process where neutrophils expel their DNA to trap pathogens—could provide clinicians with a valuable tool to anticipate disease progression, guide treatment decisions, and monitor patients over time across both acute and chronic conditions.
VolitionRx believes these findings strengthen ongoing commercial and licensing discussions for Nu.Q NETs. The company has cited a total addressable market of $2.8 billion for the technology, and this latest evidence adds to previously published data supporting its clinical utility. Dr. Andrew Retter, Medical Consultant at Volition, commented, "Introducing Nu.Q NETs into hospitals, as a treatable, trackable trait, could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors."
The ability to predict mortality and the need for renal replacement therapy in sepsis patients is a significant advancement. Current clinical tools often rely on broad scoring systems that may not capture the dynamic nature of the disease. A simple blood test that can provide objective, real-time risk assessment could revolutionize sepsis management, enabling more personalized and proactive care. This is particularly important given that sepsis is a leading cause of death in hospitals worldwide, with high morbidity and mortality rates.
Moreover, the implications extend beyond sepsis. NETosis has been implicated in various other conditions, including autoimmune diseases, thrombosis, and cancer. The Nu.Q NETs technology could potentially be applied across multiple disease states, offering a broad platform for diagnostic and monitoring applications. The company's focus on epigenetics positions it at the forefront of this emerging field, where understanding the molecular underpinnings of disease can lead to more targeted interventions.
The publication in a prestigious journal like Critical Care Medicine and the accompanying editorial highlight the credibility and potential impact of this research. As VolitionRx continues to develop and commercialize its Nu.Q tests, the evidence base supporting their clinical value grows, paving the way for adoption in healthcare settings. The company's commitment to advancing the science of epigenetics and improving outcomes for patients with life-altering diseases is evident in this latest milestone.
For more information about VolitionRx and its technologies, visit the company's website at https://volition.com/. To view the full press release, visit https://ibn.fm/RErhc.
